SI
SVA

Sensato Investors’s Sinovac Biotech, Ltd SVA Stock Holding History

Sensato Investors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-75,772
Closed -$396K – 71
2014
Q4 		$396K Buy
+75,772
New +$386K 0.12% 42

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Sensato Investors's SVA Position: Q1 2015 in Review

Sensato Investors sold out of Sinovac Biotech, Ltd (SVA) in Q1 2015, closing a stake of 75,772 shares — an estimated $396K sold.

Sensato Investors first reported a position in SVA in Q4 2014 and held it in 1 quarter. The position peaked at $396K in Q4 2014. 40 funds tracked by Wall St. Rank hold SVA as of Q1 2015.

  • Sensato Investors reported no remaining Sinovac Biotech, Ltd position as of Q1 2015 after selling out during the quarter.
  • Sensato Investors sold 75,772 Sinovac Biotech, Ltd shares in Q1 2015, an estimated $396K.
  • Sensato Investors first reported a position in Sinovac Biotech, Ltd in Q4 2014 and held it in 1 quarter.
  • Sensato Investors's Sinovac Biotech, Ltd position peaked at $396K in Q4 2014.
  • 40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2015.

Based on Sensato Investors's 13F filing for Q1 2015, filed 18 May 2015.